GlycoEra

Precision protein degradation to stop autoimmune disease at the source

Wädenswil, Switzerland · $179.0M raised

Headquarters
Wädenswil
Employees
11–50
Business Model
B2B
Total Funding
$179.0M
Last Round
$130.0M Series BMay 2025
Rounds
3

About

GlycoEra AG is a Swiss biotechnology company developing precision protein-degrading biologics to treat autoimmune diseases at their root cause. Headquartered on the Tuwag-Areal in Wädenswil, Switzerland, GlycoEra's platform selectively degrades specific circulating autoantibodies rapidly and deeply without broad immune suppression, enabling earlier disease intervention. Its lead program, GE8820, targets pathogenic IgG4 autoantibodies implicated in a range of autoimmune diseases. The company raised a $130 million Series B led by Novo Holdings in 2025 to advance GE8820 through clinical proof-of-concept.

Summary

GlycoEra is a Biotech company based in Wädenswil, Switzerland. It has raised $179.0M in total across 3 rounds, most recently a $130.0M Series B round in May 2025. Investors include Sofinnova Partners, 5AM Ventures and Roche.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series BSeries BMay 2025
$130.0M

Sign up to see all 3 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

GlycoEra on Indexed.vc
<a href="https://indexed.vc/companies/glycoera"><img src="https://indexed.vc/api/badge/company/glycoera" alt="GlycoEra on Indexed.vc" width="260" height="76" /></a>